Ocella

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ocella

Ocella is a prescription-only medication primarily used for contraception in females of reproductive potential. It is an established generic version of the reference product Yasmin, categorized as a fixed combination product containing two synthetic hormones.


Quick Facts

Property Description
Active ingredients Drospirenone (DRSP) and Ethinyl Estradiol (EE)
Form Film-coated tablets
Pharmacological class Combined Oral Contraceptive (COC)
Common use Contraception (pregnancy prevention)
Origin Synthetic

Classification and Identity

Ocella is classified by the U.S. Food and Drug Administration (FDA) as a Combined Oral Contraceptive (COC), placing it in the major pharmacological class utilized to regulate the reproductive cycle. Its primary general indication is contraception for females of reproductive potential. Pharmacological studies have widely supported the efficacy of this combination for reproductive cycle management, making it a recognized approach in women's health.


Composition and Unique Properties

The core of Ocella's composition is a fixed combination of the synthetic progestin Drospirenone (DRSP) and the synthetic estrogen Ethinyl Estradiol (EE). Both hormones are synthetic products designed to ensure a consistent hormonal effect. Ocella is supplied as a monophasic oral contraceptive, meaning that the active doses remain constant across the 21 active tablets in the typical monthly regimen.

The Drospirenone component distinguishes Ocella from combined oral contraceptives that utilize older progestins due to its unique chemical properties. Drospirenone possesses intrinsic anti-mineralocorticoid activity and antiandrogenic activity, properties consistently documented in clinical research. This means the drug has characteristics that may influence fluid balance and androgen effects, differentiating its profile compared to many other progestational compounds. While the central function of the estrogen-progestin combination is the prevention of ovulation, these additional properties are key characteristics of this specific pharmaceutical entity.

Regulatory References

  1. FDA-approved label for Ocella
  2. MedlinePlus Ocella Drug Information
  3. Ocella Label on DailyMed (Anti-mineralocorticoid activity)

What side effects are possible with Ocella?

Possible Side Effects and Safety Information

The safety profile for Ocella (drospirenone and ethinyl estradiol) is officially documented by government regulatory bodies, classifying adverse reactions by frequency and potential seriousness.

Serious and Clinically Significant Risks

The most serious documented risks involve thromboembolic events, including arterial and venous thrombosis. These include deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. The risk for these serious events is highest during the first year of use or upon restarting the medication after a break of four weeks or more.

A specific metabolic concern is the risk of hyperkalemia (high potassium levels) due to the drospirenone component, particularly in patients with pre-existing conditions like renal, hepatic, or adrenal insufficiency. Other serious events noted include elevated blood pressure, gallbladder disease, and rare hepatic tumours (benign and malignant).

Common Adverse Reactions

Adverse reactions that are frequently reported in clinical studies include:

Frequency Category Examples of Adverse Reactions
Very Common Headache, breast pain/tenderness, intermenstrual bleeding/spotting (metrorrhagia), amenorrhea (absence of menstruation).
Common Depression, mood changes, decreased libido, migraine, nausea, vomiting, abdominal pain, acne, weight gain.

Safety Restrictions and Limitations

Ocella is formally contraindicated and should not be used in individuals with a high risk for arterial or venous thrombotic diseases (e.g., uncontrolled hypertension, diabetes with vascular damage, history of VTE). It is also contraindicated in patients with known renal impairment, adrenal insufficiency, or current/past liver tumours. These limitations are put in place based on the specific risks associated with the drug's components.

Overdose and Emergency Response

Overdose and when to seek help

The following information on overdose is derived exclusively from official government regulatory documents.

Documented Overdose Manifestations

Regulatory sources explicitly define the clinical manifestations that may occur following an acute overdose of drospirenone and ethinyl estradiol. The officially documented symptoms include nausea, vomiting, and vaginal bleeding (which may present as withdrawal bleeding in females).

Required Emergency Actions

Regulatory authorities provide clear instructions on the necessary actions to take in an overdose scenario. It is mandated that the patient seek immediate medical attention or call the Poison Help Line for advice in the event a suspected overdose is identified. Immediate medical help is required for any suspected instance of overdose.

Management and Antidote Status

No serious adverse effects have been reported following acute ingestion of large doses by young children, a specific note included in regulatory information. Furthermore, official prescribing information confirms that no specific antidote is known for this combination product. As a result, the management of overdose is limited to providing symptomatic and supportive treatment under professional medical care.

The regulatory profile for Ocella overdose is defined by these specific, documented presentations and the mandatory, non-negotiable instruction to contact emergency services for immediate medical evaluation.

Therapeutic Uses of Ocella

What Ocella Treats: Main Uses and Benefits

Ocella is an oral contraceptive containing two synthetic hormones, drospirenone and ethinyl estradiol, and is commonly used as a method to prevent pregnancy. The medication contributes to its primary use in preventing pregnancy.

Beyond its role as a contraceptive, the medication is applied in addressing certain conditions characterized by periods of heightened symptoms in women who choose to use an oral contraceptive. The medication is commonly used to help with two other approved indications: treating moderate acne vulgaris and managing symptoms that interfere with daily functioning associated with Premenstrual Dysphoric Disorder (PMDD).

Expanded Symptomatic Support

In clinical settings that involve acute or unstable symptom patterns, this medication supports patients during episodes of heightened discomfort. For example, regarding PMDD, the medication may assist with easing the systemic burden of symptoms of increased neurological or muscular activity. For patients with moderate acne, the medication is considered relevant for easing a symptom cluster that may become intense or disruptive.

The goal of these uses contributes to easing the overall symptom load and supports general well-being during symptomatic phases. The medication is applied when appropriate to help with managing PMDD.

Quick Fact: Supports patients with symptoms related to physical discomfort and symptoms related to systemic imbalance.

Regulatory References

  1. NIH DailyMed Official Indications for Drospirenone and Ethinyl Estradiol

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Ocella

The eligibility for Ocella (drospirenone and ethinyl estradiol) is strictly defined by regulatory documents, limiting its use to females of reproductive potential who meet specific health criteria.

Populations for whom use is Contraindicated

Ocella is contraindicated (absolutely prohibited) in individuals with several specific conditions, primarily related to the risk of blood clots and hormone sensitivity. These include:

  • A high risk of arterial or venous thrombotic diseases (e.g., current or history of DVT, PE, stroke, or CAD, or known thrombophilias).
  • Current or history of breast cancer or other estrogen- or progestin-sensitive tumors.
  • Severe hepatic disease, liver tumors, renal insufficiency, or adrenal insufficiency.
  • Uncontrolled hypertension or diabetes mellitus with vascular disease.
  • Confirmed or suspected pregnancy.

Age and Physiological Restrictions

Use is not indicated before menarche (onset of menstruation) or in postmenopausal women. Furthermore, the medicine is not recommended for use in women who are breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Ocella (drospirenone/ethinyl estradiol) is structured around two key pharmacological effects: metabolic interference and pharmacodynamic reinforcement.


Interaction Scope and Restrictions

Category Regulatory Summary
Medicinal product categories with documented interactions Enzyme-Inducing Substances (CYP3A4 inducers), Strong CYP3A4 Inhibitors, Potassium-Raising Medications (e.g., ACE inhibitors, ARBs, potassium-sparing diuretics), and specific Hepatitis C combination products.
Specific interacting medicines (if explicitly listed) Ombitasvir/paritaprevir/ritonavir (with or without dasabuvir), Rifampicin, Ketoconazole, and Lamotrigine are cited in official documents.
Mechanistic basis of interactions Pharmacokinetic interaction via altered metabolism (CYP3A4 induction/inhibition) and Pharmacodynamic interaction via additive effect on serum potassium.
Interaction-related restrictions Co-administration is formally contraindicated with specific Hepatitis C combination products due to the documented potential for significant ALT (liver enzyme) elevations.

Official Interaction Statements

  • Substances classified as CYP3A4 inducers (e.g., rifampicin, certain anticonvulsants, St. John's Wort) decrease the plasma concentrations of the contraceptive components, which is officially stated to lead to a reduction in effectiveness.
  • Co-administration with potassium-raising drugs carries a documented risk of hyperkalemia due to the anti-mineralocorticoid activity of the drospirenone component.
  • For patients using potassium-raising medications, the official label requires checking serum potassium concentration during the initial treatment cycle.
  • The ethinyl estradiol component is expected to substantially decrease the plasma concentration of the anticonvulsant lamotrigine.
  • Consumption of Grapefruit Juice may increase the plasma concentrations of drospirenone by inhibiting its metabolism.

Mechanism of Action

Central Endocrine Inhibition of the HPO Axis

The primary mechanism involves the establishment of strong negative feedback on the Hypothalamic-Pituitary-Ovarian (HPO) axis. Both Ethinyl Estradiol (EE) and Drospirenone (DRSP) act as agonists at their respective Estrogen and Progesterone Receptors, centrally suppressing the release of pituitary hormones FSH and LH. This inhibition prevents the LH surge , which is the biological trigger for oocyte release, leading directly to the physiological effect of anovulation (the cessation of oocyte release).

Peripheral Barrier Modulation

The progestogenic action alters the glandular function of the cervix, causing the cervical mucus to thicken and become less permeable. Simultaneously, the hormones modify the uterine lining (endometrium) to be structurally unreceptive. These peripheral alterations establish two physical and biochemical barriers that reinforce the core anovulatory mechanism.

Unique Anti-Mineralocorticoid and Antiandrogenic Activity

Drospirenone acts as a competitive antagonist at the Mineralocorticoid Receptor (MR) and the Androgen Receptor (AR). Blocking the MR influences the Renin-Angiotensin-Aldosterone System (RAAS), promoting sodium and water excretion (natriuresis), which is a defining physiological consequence of this specific mechanism. Antagonism at the AR limits androgen-mediated signaling at target tissues.

Dosage and Administration Information

How to Use Ocella: Official Administration Guidelines

Ocella (drospirenone 3 mg / ethinyl estradiol 0.03 mg) is administered as a fixed-dose oral combined contraceptive, with its usage governed by a specific, standardized regimen. The administration follows a cyclic 28-day schedule for continuous, ongoing use.


Administration Protocol

The medication is supplied as a 28-day pack consisting of 21 active (yellow) tablets and 7 inactive (white) placebo tablets. The fundamental instruction is to take one tablet orally once daily at the same time every day to maintain consistent drug exposure. Tablets must be swallowed whole and taken strictly in the sequence directed on the blister packaging. The regimen may be initiated using either the Day 1 Start method or the Sunday Start method.

Administration Detail Labeled Instruction
Route of Administration Oral
Daily Timing Once daily, at the same time each day
Timing Relative to Meals May be taken with or without food
Dose Pattern Fixed dose: 21 days active tablets / 7 days inactive tablets

Usage Structure and Continuity

Adherence to the 28-day cycle is essential, requiring the user to begin a new pack immediately after finishing the previous one, regardless of whether a withdrawal bleed has occurred or is still in progress. Specific procedural instructions exist for handling a missed active dose, which vary based on the number of tablets missed and the week of the cycle. Additionally, the fixed-dose regimen is indicated for use in postpubertal adolescents under the age of 18.

Recent Clinical Evidence

Ocella: Recent Clinical Evidence

Ocella was evaluated in research exploring methods for preventing pregnancy through large-scale, controlled, and extended observational studies. Research examined generally healthy females of reproductive potential, and studies monitored outcomes that included the Pearl Index (which measures the rate of pregnancies that occur during use) as well as measures related to cycle control. The data show patterns related to the study's focus on preventing ovulation. Long-term effects are not fully established regarding reproductive outcomes following discontinuation, and there is limited information from trials about complex, real-world adherence patterns.

The medication's use in managing skin conditions was evaluated in randomized, double-blind, placebo-controlled trials. These studies focused on women with moderate facial acne vulgaris who were also seeking an oral contraceptive. Research monitored changes in the skin by tracking counts of lesions and using the Investigator's Global Assessment (IGA) scale. The research highlights the measurement of changes in lesion counts during the study period, but follow-up durations were limited for assessing maintenance beyond the initial six cycles of use. Data are insufficient for groups not requiring oral contraception.

Ocella was studied for its application in managing symptoms related to Premenstrual Dysphoric Disorder (PMDD), a condition characterized by fluctuating or episodic manifestations. The research involved randomized, placebo-controlled trials and applied validated tools to track outcomes related to episodic or acute changes in mood and physical well-being. The durability of the patterns observed after the short treatment period is not well-characterized. The evidence base is limited to women with a confirmed PMDD diagnosis, and comparative evidence against non-hormonal therapies is lacking.

Overall, most primary research was observed in short-term trials (months to one year), meaning there is limited information concerning the research scope over many years of continuous use. Data for certain subgroups, such as those with pre-existing chronic conditions, remain limited.

Key Studies & References

  1. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation (Multicenter, Double-Blind, Placebo-Controlled Crossover Study for PMDD)
  2. A combined oral contraceptive containing 3-mg drospirenone/20-μg ethinyl estradiol in the treatment of acne vulgaris: A randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment
  3. Drospirenone/ethinylestradiol: a review on efficacy and noncontraceptive benefits

Frequently Asked Questions (FAQ)

Common questions about Ocella (FAQ)

Q: Is Ocella used for treating conditions other than birth control?

Ocella is primarily indicated for the prevention of pregnancy. However, similar regulatory-approved products containing drospirenone and ethinyl estradiol have also received approval from the FDA for the treatment of moderate acne in women who desire an oral contraceptive and for the treatment of Premenstrual Dysphoric Disorder (PMDD). Official information provides details on the evidence supporting these other potential uses.

Q: What should I do if I am traveling across time zones while taking Ocella?

Official administration instructions emphasize taking one tablet daily at the same time every day. When traveling, the critical factor is maintaining this consistent 24-hour dosing interval for maximizing effectiveness. The consistent adherence to this interval is the priority when adjusting to a new time zone.

Q: Does taking Ocella affect future fertility?

According to official product information, there is no evidence that the use of oral contraceptives causes long-term infertility. It is noted that it may take longer than usual for a woman’s regular menstrual cycles and her ability to become pregnant to return after stopping the medication.

Q: Are there any herbal supplements that are known to interact with Ocella?

Yes, regulatory documents explicitly list products containing the herbal supplement St. John's wort as a potential interaction risk. St. John’s wort may decrease the effectiveness of combined oral contraceptives like Ocella and could increase the incidence of breakthrough bleeding.

Q: Is Ocella safe to use if I have a history of migraines?

Official warnings state that combined oral contraceptives, including Ocella, are contraindicated in women who experience migraine with aura due to an increased risk of stroke. Women who have a history of headaches are advised to seek evaluation by a healthcare professional, especially concerning any migraines.

Q: Why do some people switch from another pill to Ocella?

The progestin component in Ocella, drospirenone, has unique anti-mineralocorticoid activity, a property consistently documented in clinical research. This characteristic means the drug may influence the body's fluid balance, which is a differentiating factor compared to many pills containing older progestins.

Q: Are there specific instructions for the non-active pills in the Ocella pack?

The pack includes seven inactive (white) tablets that do not contain hormones. Instructions indicate that these pills are taken in the sequence directed on the blister pack, as they are included solely to help maintain the 28-day cycle regimen and the daily pill-taking habit.

Q: Can taking antibiotics reduce the protection provided by Ocella?

Official labeling notes that most antibiotics have not shown consistent effects on the hormone levels in oral contraceptives. However, the specific antibiotic rifampin is explicitly listed as a drug that can reduce the effectiveness of Ocella. It is important to discuss all concurrent medications with a healthcare provider.

Q: Is a follow-up appointment needed after starting Ocella?

Regulatory documents require specific monitoring for certain users. For women taking other medications that raise potassium levels, the official label requires checking the patient's serum potassium concentration during the initial treatment cycle due to the unique activity of the drospirenone component.

Q: Why does the pack have inactive pills, and what do they contain?

The pack contains seven inactive (placebo) tablets that do not have any hormones. These pills are included to allow the user to maintain the habit of taking one pill every day and to ensure the timely start of the next cycle pack.

Q: What is the official designation of Ocella regarding pregnancy risk categories?

Official information emphasizes that combined oral contraceptives are contraindicated and have no use during a confirmed or suspected pregnancy. Regulatory categories for pregnancy risk are undergoing transition, but the fundamental regulatory position is that the drug is not used when pregnancy is confirmed.

Q: Are there any known interactions between Ocella and seizure medications?

Yes, official documents indicate potential interactions. Certain anticonvulsants (seizure medications) can decrease the effectiveness of Ocella by altering its metabolism. The estrogen component in Ocella can also significantly decrease the concentration of the anticonvulsant lamotrigine.

Q: Why is it important to report all medications to a healthcare professional before starting Ocella?

Reporting all medications is crucial because many common drugs and supplements can interact with Ocella. These interactions can either cause a serious risk of hyperkalemia (high potassium) or lead to a reduction in contraceptive effectiveness.

Q: Why does Ocella come with a patient information leaflet?

As a prescription drug, particularly a combined oral contraceptive with documented serious risks, the FDA requires a Patient Information Leaflet to be provided. This leaflet is designed to inform the patient about the drug’s proper usage, potential risks, and adverse reactions.

Q: How quickly does Ocella start to work for its main purpose?

According to official administration guidance, if the pill is not started on the first day of menstruation, it is not considered effective as a contraceptive until after the first 7 consecutive days of use. Official guidance indicates that a non-hormonal back-up method is used during this initial period.

Q: Are certain side effects with Ocella considered temporary?

Official patient information indicates that certain adverse reactions, such as nausea, headache, spotting, or missed periods, may occur frequently during the first few months of use. It is suggested that these effects may subside, but the official guidance suggests consulting a healthcare provider if these effects last or worsen.

Q: Can taking ibuprofen interact with Ocella?

Official warnings state that the chronic or regular use of nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen may carry a specific risk. This is because they can potentially increase the risk of high potassium levels (hyperkalemia) due to the presence of drospirenone in Ocella.

Q: Does caffeine or alcohol affect how Ocella works?

Regulatory documents indicate that the estrogen component of Ocella may moderately increase the blood levels of caffeine, which could increase the likelihood of caffeine's side effects. Official information also notes a minor interaction with alcohol.

Q: Can Ocella be used by women over the age of 35?

Official boxed warnings highlight that cigarette smoking increases the risk of serious cardiovascular events, and this risk dramatically increases in women over 35 years of age who smoke. The label advises assessing cardiovascular risk factors before starting the medication in all women, particularly those over 35.

Q: What if I vomit shortly after taking an Ocella pill?

If vomiting or severe diarrhea occurs within 3 to 4 hours of taking an active pill, official guidance recommends treating the situation as a missed active pill because absorption may not be complete. Users are advised to follow the specific instructions for missed doses provided in the patient information leaflet.

Q: What are the warning signs of a serious side effect related to blood clots while using Ocella?

The official patient information advises seeking medical help immediately if symptoms of serious blood clots occur. These signs include unexplained, sudden, severe headaches, trouble speaking, sudden vision changes, pain/swelling/warmth in the leg/calf, or shortness of breath/chest pain.

Q: Does Ocella influence cholesterol levels?

Official product information notes that Ocella and similar combined oral contraceptives may cause adverse lipid metabolic effects (changes in cholesterol or fat levels) in some patients. The label notes that women with uncontrolled dyslipidemia are a population for whom caution is typically advised.

Q: Are there differences in effectiveness if Ocella is taken in the morning versus the evening?

The official administration instruction is to take the pill once daily at the same time every day, ensuring the interval between doses does not exceed 24 hours. Therefore, the consistent adherence to the 24-hour interval is the priority over the specific time of day (morning or evening) chosen.

Q: Can I stop taking Ocella at any time?

A woman can stop taking the medication whenever she chooses. However, protection from pregnancy will immediately cease, and a patient may experience temporary effects like irregular periods while the body adjusts back to its natural cycle.

Q: What if I need surgery while taking Ocella?

Regulatory warnings indicate that the combined oral contraceptive is typically discontinued at least 4 weeks before and for 2 weeks after major surgery or any procedure associated with an increased risk of thromboembolism (blood clots). This is a procedural safeguard to manage blood clot risk.

Q: How long after stopping Ocella can one expect their normal cycle to return?

Official patient information indicates that it may take several months for a woman’s regular menstrual cycles to return and regulate after stopping hormonal birth control. If a regular period has not returned after three months, the official guidance suggests consulting a doctor.

Q: What is the difference between Ocella and Yaz?

Both Ocella and Yaz contain the hormones drospirenone and ethinyl estradiol, but they are distinct products with different doses. Ocella contains 0.03 mg of ethinyl estradiol, while the brand-name product Yaz contains a lower dose of 0.02 mg of ethinyl estradiol.

Q: Does Ocella offer protection against sexually transmitted infections?

No, official regulatory information clearly states that combined oral contraceptives, including Ocella, do not protect against HIV/AIDS, or other sexually transmitted infections (STIs). Non-hormonal barrier methods are generally indicated for protection against STIs.

Q: Can Ocella cause changes to vision or use of contact lenses?

Official safety documents mention that if a patient wears contact lenses, they may develop vision problems or find that the lenses begin to feel uncomfortable while using the medication. The official guidance suggests consulting an eye care specialist if these issues occur.

How should Ocella be stored and disposed of?

How to Store and Dispose of Ocella

The storage and handling of Ocella (drospirenone and ethinyl estradiol) must follow official regulatory requirements to maintain product stability and safety.

Storage Requirements

The medication must be stored at Controlled Room Temperature (CRT), which is defined as 20 C to 25 C (68 F to 77 F). Permitted temperature excursions range from 15 C to 30 C (59 F to 86 F). The tablets must be kept in the original container to provide protection from light and moisture. Ocella must be stored out of the reach of children.


Disposal Instructions

Unused or expired medication must be disposed of according to local regulations. General guidance advises against flushing the tablets down a toilet or pouring them down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ocella found in:

A-Z Index: